BioCardia logo
BioCardia BCDA
$ 1.27 0.0%

Quarterly report 2025-Q3
added 11-12-2025

report update icon

BioCardia Cash Flow 2011-2025 | BCDA

Annual Cash Flow BioCardia

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-9.97 M -10.6 M -10.4 M -12.4 M -9.44 M -11.1 M -8.67 M -5.52 M -7.02 M - 27 K -310 K -3.09 M

Depreciation & Amortization

84 K 82 K 60 K 68 K 111 K 88 K 78 K 39 K 47 K - - - -

Accounts Payables

890 K 683 K 507 K 746 K 914 K 1.02 M 902 K 525 K - - - - -

Accounts Receivables

63 K 201 K 147 K 232 K 147 K 274 K 95 K 74 K - - - - 67 K

Total Inventories

- - - - 4 K 141 K 191 K 135 K - - - - -

All numbers in USD currency

Quarterly Cash Flow BioCardia

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -1.62 M - - - -1.53 M - - - -2.56 M - -7.56 M -5.56 M -2.91 M - -7.39 M -4.75 M -1.88 M - -8.94 M -5.34 M -2.99 M - -6.19 M -4.72 M -2.46 M - -7.82 M -5.81 M -3.04 M - -6.15 M -4.37 M -2.28 M - -3.01 M - - - - - - - - - 27 K - - 1 K -14 K - -755 K -694 K -26 K - -2.28 M -2.36 M -558 K

Depreciation & Amortization

4 K 5 K 12 K - 16 K 17 K 19 K - 21 K 21 K 22 K - 29 K 21 K 16 K - 45 K 30 K 14 K - 52 K 36 K 22 K - 78 K 49 K 23 K - 66 K 44 K 22 K - 57 K 36 K 13 K - 30 K 21 K 10 K - - - - - - - - - - - - - - - - - - - -

Accounts Payables

1.08 M 1.23 M 818 K 385 K 569 K 1.45 M 1.03 M 890 K 507 K 686 K 861 K 683 K 887 K 999 K 764 K 507 K 846 K 970 K 850 K 746 K 746 K 746 K 746 K 914 K 914 K 914 K 914 K 743 K 743 K 1.02 M 1.02 M 902 K 902 K 902 K 902 K 525 K 525 K 525 K 525 K 542 K - - - - - - - - - - - - - - - 127 K - - -

Accounts Receivables

- 10 K - - 10 K 10 K 58 K 63 K 104 K 115 K 153 K 201 K 300 K 211 K 326 K 147 K 198 K 229 K 190 K 232 K 232 K 232 K 232 K 147 K 147 K 147 K 147 K 274 K 274 K 274 K 274 K 95 K 95 K 95 K 95 K 74 K 74 K 74 K 74 K 107 K - - - - - - - - - - - - 24 K 24 K 24 K 67 K 67 K 67 K 67 K

Total Inventories

- - - - - - - - - - - - - - - - - - - - - - - 4 K 4 K 4 K 4 K 141 K 141 K 141 K 141 K 191 K 191 K 191 K 191 K 135 K 135 K 135 K 135 K 759 K - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company BioCardia, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.79 2.35 % $ 795 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.04 4.83 % $ 235 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 0.93 -8.81 % $ 257 K usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 212.81 1.71 % $ 5 B danmarkDanmark
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
BioVie BioVie
BIVI
$ 1.27 -3.05 % $ 1.88 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.1 0.16 % $ 7.46 B australiaAustralia
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.37 2.06 % $ 814 M usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 26.83 0.94 % $ 1.73 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 95.03 0.95 % $ 27.2 B germanyGermany
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 26.81 1.36 % $ 1.3 B usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 83.59 1.95 % $ 8.63 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.48 0.96 % $ 139 M usaUSA
CorMedix CorMedix
CRMD
$ 12.19 1.75 % $ 621 M usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.18 -25.03 % $ 392 M israelIsrael
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 591.15 0.02 % $ 44.8 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.53 -0.39 % $ 15.9 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 92.45 0.34 % $ 96.9 B britainBritain
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA